CA2847151C - Assessing stem cells for contamination using microrna expression profiles - Google Patents
Assessing stem cells for contamination using microrna expression profiles Download PDFInfo
- Publication number
- CA2847151C CA2847151C CA2847151A CA2847151A CA2847151C CA 2847151 C CA2847151 C CA 2847151C CA 2847151 A CA2847151 A CA 2847151A CA 2847151 A CA2847151 A CA 2847151A CA 2847151 C CA2847151 C CA 2847151C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- micro
- cell
- stem cells
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims description 130
- 108091070501 miRNA Proteins 0.000 title claims description 53
- 210000000130 stem cell Anatomy 0.000 title claims description 41
- 238000011109 contamination Methods 0.000 title claims description 14
- 210000004027 cell Anatomy 0.000 claims description 329
- 239000002679 microRNA Substances 0.000 claims description 156
- 238000000034 method Methods 0.000 claims description 70
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 14
- 230000011712 cell development Effects 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 9
- 238000012423 maintenance Methods 0.000 claims description 4
- 238000012606 in vitro cell culture Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims 6
- 238000001303 quality assessment method Methods 0.000 claims 3
- 238000009168 stem cell therapy Methods 0.000 claims 1
- 238000009580 stem-cell therapy Methods 0.000 claims 1
- 108091027963 non-coding RNA Proteins 0.000 abstract description 120
- 102000042567 non-coding RNA Human genes 0.000 abstract description 119
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 108700011259 MicroRNAs Proteins 0.000 description 134
- 238000004458 analytical method Methods 0.000 description 20
- 230000004069 differentiation Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 238000004113 cell culture Methods 0.000 description 18
- 230000004075 alteration Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 238000012360 testing method Methods 0.000 description 12
- 238000011529 RT qPCR Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 238000000513 principal component analysis Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000003908 quality control method Methods 0.000 description 9
- 239000000306 component Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 210000003995 blood forming stem cell Anatomy 0.000 description 7
- 238000007405 data analysis Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000010208 microarray analysis Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000010364 biochemical engineering Methods 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 5
- 239000013614 RNA sample Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- DCCYTKKDAZEVLY-UHFFFAOYSA-N 2-(2-oxo-2-thiophen-2-ylethyl)sulfanyl-4,6-dithiophen-2-ylpyridine-3-carbonitrile Chemical compound C=1C=CSC=1C(=O)CSC(C=1C#N)=NC(C=2SC=CC=2)=CC=1C1=CC=CS1 DCCYTKKDAZEVLY-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 101710086015 RNA ligase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000036978 cell physiology Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LYOKOJQBUZRTMX-UHFFFAOYSA-N 1,3-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxy]-2,2-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxymethyl]propane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)OCC(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F LYOKOJQBUZRTMX-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 101710124239 Poly(A) polymerase Proteins 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003181 biological factor Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229960000106 biosimilars Drugs 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- OHOQEZWSNFNUSY-UHFFFAOYSA-N Cy3-bifunctional dye zwitterion Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C2=CC=C(S(O)(=O)=O)C=C2C(C)(C)C1=CC=CC(C(C1=CC(=CC=C11)S([O-])(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O OHOQEZWSNFNUSY-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091067468 Homo sapiens miR-210 stem-loop Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101001041669 Oryctolagus cuniculus Corticostatin 1 Proteins 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 108010051489 calin Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1014049.9 | 2010-08-23 | ||
| GBGB1014049.9A GB201014049D0 (en) | 2010-08-23 | 2010-08-23 | Cell characterisation |
| PCT/GB2011/001241 WO2012025709A1 (en) | 2010-08-23 | 2011-08-19 | Cell characterisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2847151A1 CA2847151A1 (en) | 2012-03-01 |
| CA2847151C true CA2847151C (en) | 2023-11-28 |
Family
ID=42984495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2847151A Active CA2847151C (en) | 2010-08-23 | 2011-08-19 | Assessing stem cells for contamination using microrna expression profiles |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20130196875A1 (enExample) |
| EP (1) | EP2609217B1 (enExample) |
| JP (1) | JP2013535979A (enExample) |
| KR (1) | KR20140006775A (enExample) |
| CN (1) | CN103403180A (enExample) |
| AU (1) | AU2011294936A1 (enExample) |
| BR (1) | BR112013004202A2 (enExample) |
| CA (1) | CA2847151C (enExample) |
| GB (1) | GB201014049D0 (enExample) |
| IL (1) | IL224888B (enExample) |
| SG (2) | SG10201506595QA (enExample) |
| WO (1) | WO2012025709A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2859119A2 (en) * | 2012-06-12 | 2015-04-15 | Institute for Systems Biology | Complex rna composition of bodily fluids |
| WO2017160880A1 (en) * | 2016-03-14 | 2017-09-21 | Aelan Cell Technologies, Inc. | Compositions and methods for the quality control of stem cell preparations |
| SG11201809902QA (en) | 2016-05-09 | 2018-12-28 | Sistemic Scotland Ltd | Functional prediction of cellular functions by means of microrna expression profiling in mesenchymal stem cells |
| JP6629770B2 (ja) * | 2017-01-19 | 2020-01-15 | シスメックス株式会社 | 細胞の分化状態を評価する方法 |
| JP6918062B2 (ja) * | 2017-01-19 | 2021-08-11 | シスメックス株式会社 | 細胞の分化状態を評価する方法 |
| GB2570404A (en) * | 2018-01-22 | 2019-07-24 | Sistemic Scotland Ltd | Cell contamination assay |
| WO2020072545A1 (en) * | 2018-10-01 | 2020-04-09 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | MicroRNA TRANSCRIPTIONAL SIGNATURE (miR-TS) EVALUATION OF STEM CELLS |
| CN113658636B (zh) * | 2021-07-22 | 2025-08-05 | 未来智人再生医学研究院(广州)有限公司 | 一种评估多能干细胞质量的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050123952A1 (en) * | 2003-09-04 | 2005-06-09 | Griffey Richard H. | Methods of rapid detection and identification of bioagents using microRNA |
| JP5697297B2 (ja) * | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロｎａｓおよびその使用 |
| EP1966390A1 (en) * | 2005-12-29 | 2008-09-10 | Exiqon A/S | Detection of tissue origin of cancer |
| CN101316935B (zh) * | 2006-11-28 | 2012-02-29 | 博奥生物有限公司 | 一种用于诊断食道癌的芯片 |
| CN101622350A (zh) * | 2006-12-08 | 2010-01-06 | 奥斯瑞根公司 | 作为干预治疗靶标的miR-126调控基因和通路 |
| WO2008112283A2 (en) * | 2007-03-12 | 2008-09-18 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment |
| WO2009036332A1 (en) * | 2007-09-14 | 2009-03-19 | Asuragen, Inc. | Micrornas differentially expressed in cervical cancer and uses thereof |
| WO2009062503A1 (en) * | 2007-11-14 | 2009-05-22 | Dandrit Biotech A/S | Micro rnas as markers of the functional state of a dendritic cell |
| CA2717030A1 (en) * | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof |
| US20100003674A1 (en) * | 2008-07-03 | 2010-01-07 | Cope Frederick O | Adult stem cells, molecular signatures, and applications in the evaluation, diagnosis, and therapy of mammalian conditions |
| WO2010082039A1 (en) * | 2009-01-19 | 2010-07-22 | Sistemic Scotland Limited | Methods employing non-coding rna expression assays |
-
2010
- 2010-08-23 GB GBGB1014049.9A patent/GB201014049D0/en not_active Ceased
-
2011
- 2011-08-19 SG SG10201506595QA patent/SG10201506595QA/en unknown
- 2011-08-19 US US13/818,750 patent/US20130196875A1/en not_active Abandoned
- 2011-08-19 JP JP2013525347A patent/JP2013535979A/ja active Pending
- 2011-08-19 BR BR112013004202A patent/BR112013004202A2/pt not_active IP Right Cessation
- 2011-08-19 WO PCT/GB2011/001241 patent/WO2012025709A1/en not_active Ceased
- 2011-08-19 CN CN2011800509567A patent/CN103403180A/zh active Pending
- 2011-08-19 AU AU2011294936A patent/AU2011294936A1/en not_active Abandoned
- 2011-08-19 SG SG2013038724A patent/SG190837A1/en unknown
- 2011-08-19 KR KR1020137007313A patent/KR20140006775A/ko not_active Ceased
- 2011-08-19 CA CA2847151A patent/CA2847151C/en active Active
- 2011-08-19 EP EP11760806.7A patent/EP2609217B1/en active Active
-
2013
- 2013-02-24 IL IL224888A patent/IL224888B/en active IP Right Grant
-
2016
- 2016-08-22 US US15/243,202 patent/US20170218446A1/en not_active Abandoned
-
2019
- 2019-08-26 US US16/551,337 patent/US20200080148A1/en not_active Abandoned
-
2022
- 2022-12-13 US US18/079,922 patent/US20230183803A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG190837A1 (en) | 2013-07-31 |
| BR112013004202A2 (pt) | 2019-09-24 |
| IL224888B (en) | 2020-10-29 |
| SG10201506595QA (en) | 2015-10-29 |
| US20200080148A1 (en) | 2020-03-12 |
| EP2609217A1 (en) | 2013-07-03 |
| KR20140006775A (ko) | 2014-01-16 |
| JP2013535979A (ja) | 2013-09-19 |
| EP2609217B1 (en) | 2019-03-27 |
| US20130196875A1 (en) | 2013-08-01 |
| CA2847151A1 (en) | 2012-03-01 |
| GB201014049D0 (en) | 2010-10-06 |
| WO2012025709A1 (en) | 2012-03-01 |
| CN103403180A (zh) | 2013-11-20 |
| US20230183803A1 (en) | 2023-06-15 |
| US20170218446A1 (en) | 2017-08-03 |
| AU2011294936A1 (en) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230183803A1 (en) | Cell characterisation | |
| US20250243480A1 (en) | Method to Connect Chromatin Accessibility and Transcriptome | |
| Sasagawa et al. | Quartz-Seq2: a high-throughput single-cell RNA-sequencing method that effectively uses limited sequence reads | |
| Pollen et al. | Low-coverage single-cell mRNA sequencing reveals cellular heterogeneity and activated signaling pathways in developing cerebral cortex | |
| Szafranska et al. | Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling | |
| Ortmann et al. | Naive pluripotent stem cells exhibit phenotypic variability that is driven by genetic variation | |
| WO2020206285A1 (en) | Methods and applications for cell barcoding | |
| CN114875118B (zh) | 确定细胞谱系的方法、试剂盒和装置 | |
| US20220356461A1 (en) | High-throughput single-cell libraries and methods of making and of using | |
| Andrei et al. | Differential miRNA expression profiles in cumulus and mural granulosa cells from human pre-ovulatory follicles | |
| Noli et al. | Human embryos created by embryo splitting secrete significantly lower levels of miRNA-30c | |
| Stelzer et al. | Global analysis of parental imprinting in human parthenogenetic induced pluripotent stem cells | |
| Li et al. | Small RNA transcriptome analysis using parallel single-cell small RNA sequencing | |
| Martinez | Analysis of gene expression and gene silencing in human macrophages | |
| Chakraborty et al. | Single‐cell sequencing of miRNAs: A modified technology | |
| Git et al. | PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes | |
| Juzenas et al. | inDrops-2: a flexible, versatile and cost-efficient droplet microfluidic approach for high-throughput scRNA-seq of fresh and preserved clinical samples | |
| Ruan et al. | Expression profile of long non-coding RNAs during the differentiation of human umbilical cord derived mesenchymal stem cells into cardiomyocyte-like cells | |
| Sampath et al. | Identifying translationally regulated genes during stem cell differentiation | |
| Brodská | Single-cell RNA sequencing in leukemia | |
| Wang et al. | Single-cell microRNA/mRNA co-sequencing reveals non-genetic heterogeneity and novel regulatory mechanisms | |
| Schmauch et al. | Global MicroRNA Profiling of Vascular Endothelial Cells | |
| HK40068328A (en) | High-throughput single-cell libraries and methods of making and of using | |
| Sasagawa et al. | Quartz-Seq2: 3 | |
| Ciani | Regulatory modules discovery and mesenchymal stem cells characterization from high-throughput cancer genomics data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160818 |
|
| EEER | Examination request |
Effective date: 20160818 |
|
| EEER | Examination request |
Effective date: 20160818 |
|
| EEER | Examination request |
Effective date: 20160818 |
|
| EEER | Examination request |
Effective date: 20160818 |
|
| EEER | Examination request |
Effective date: 20160818 |